media – Page 4 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

The “King of Medicine” in Guangdong sold for 56.6 billion yuan.

The period from 2016 to 2025 marks a decade of continuous reform in China’s pharmaceutical industry. Centralized procurement policies are reshaping the industry’s logic, and a wave of innovative drugs is surging forward. In this profound industrial transformation, Guangdong’s pharmaceutical companies have delivered a remarkable performance . the rise of Guangdong’s “King of Medicines” from the perspectives of enterprise and brand dimensions, based on the terminal sales data of Guangdong pharmaceutical companies and drug brands from 2016 to 2025, using data from Yaozhi Data . Note: The drugs mentioned in this article cover various types of drugs, including innovative drugs, generic drugs, and traditional Chinese medicines; sales data comes from Yaozhi Data; the sales figures are based on the sales performance of pharmaceutical companies registered in Guangdong (including 21 prefecture-level cities) across the country in terms of terminal sales (hospitals + retail + e-commerce channels). 01 The King of Pharmaceutical ...
- Source: drugdu
- 68
- September 8, 2026
Analytica Anacon India

Organiser：Messe München International Time：September 10th – 12th, 2026 Address：HITEX Exhibition Centre Izzat Nagar Hyderabad 500 032, A.P. Exhibition hall：Hyderabad International Trade Exposition Centre Product range: Analytical Technology: Analytical instruments and equipment, microscopes and optical imaging processing, spectroscopy and chromatography products Testing, Measurement and Quality Control: Industrial quality control, material property identification technology, material testing, pharmaceutical and industrial quality control Laboratory Equipment: Laboratory apparatus and equipment, laboratory data and archiving management equipment, chemicals, reagents and consumables Life Sciences and Testing & Measurement Technology: Bioanalysis, biochemical reagents and bioinformatics technology, laboratory testing and measurement supplies About Analytica Anacon India： Analytica Anacon India is the most influential exhibition for laboratory, analytical and biochemical technologies in India and South Asia. This initiative will make the Indian Laboratory and Biotechnology Exhibition the largest and most influential professional exhibition for the laboratory, analytical and biochemical technology industry in India and even the entire South ...
- Source: drugdu
- 68
- September 8, 2026
【EXPERT Q&A】For suppliers without mature export cases, what else can be written on the enterprise page?

Drugdu.com expert’s response: Many new suppliers on the platform get stuck on one question when completing their company profile page: “We don’t have many mature export cases yet, so is there nothing substantial to write in our company introduction?” This is especially true for enterprises in the API, excipient, pharmaceutical intermediate and medical device sectors. If they do not yet have stable overseas orders or representative clients, they can easily end up with a very empty and generic company page. Common generic lines include: “We are a professional supplier.” “We provide high quality products.” “We have competitive prices and good service.” These statements are not technically wrong, but overseas buyers can hardly tell exactly what the enterprise is capable of delivering after reading them. Not having mature export cases does not mean your company page has to be empty. When buyers visit a company page, they do not only look ...
- Source: drugdu
- 78
- September 7, 2026
【EXPERT Q&A】The quotation was sent out for three days without a reply. What else can be sent during the second follow-up?

Drugdu.com expert’s response: When doing pharmaceutical foreign trade, many suppliers have encountered this situation: A buyer sends an inquiry asking about products, specifications and prices. The sales team sorts out materials, checks costs, and sends out a quotation. After the email or WhatsApp message is sent, three days pass with no reply. At this point, many people will write their second follow-up like this: “Any update?” Or: “Have you checked our quotation?” These lines are not completely useless, but their effect is usually limited. There are many reasons why a buyer does not reply: they may still be comparing prices internally, waiting for confirmation from an end customer, feeling that some information is missing from the quotation, or contacting multiple suppliers at the same time. If the second follow-up only presses for a reply, the buyer has no new information to respond with, and the communication can easily come to a standstill. For the ...
- Source: drugdu
- 87
- September 4, 2026
The snoring of 1 billion people can finally be cured! The FDA has accepted the marketing application for a new oral drug for obstructive sleep apnea.

If all goes well, a new drug for snoring will be approved early next year, potentially becoming the world’s first landmark drug targeting the neuromuscular causes of snoring . In July, Phase III clinical data of AD109 , a new oral drug for obstructive sleep apnea ( OSA ), was published in the American Journal of Respiratory and Critical Care Medicine . The data showed that the apnea-hypopnea index (AHI) decreased by 44.1% after treatment , and the oxygen depletion index and blood oxygen saturation were improved, indicating a significant improvement in the severity of OSA. picture AD109, developed by the US biotechnology company Apnimed , consists of the marketed drug atomoxetine and a novel isomer, R -oxybutynin , derived from the older drug oxybutynin. It works by modulating nerve signals, allowing patients to maintain airway tone during sleep and reducing the occurrence of sleep apnea. Its new drug application ...
- Source: drugdu
- 85
- September 3, 2026
Biosimilar Export Accelerates! Jianyou’s Adalimumab Receives FDA Approval for Additional Manufacturing Site | Overseas Expansion News

On September 1, Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. (Jianyou, 603707.SH) announced that its subsidiary, Emerge Bioscience Pte. Ltd., recently received a letter from the U.S. Food and Drug Administration (FDA) approving an additional manufacturing site for adalimumab injection (40 mg/0.8 mL, single-dose) under BLA No. 761216. The approval authorizes production at the Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. facility. Adalimumab injection, a biosimilar, was first approved by the U.S. FDA on December 17, 2021. Its indications cover multiple autoimmune diseases including rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis, and plaque psoriasis. The approval of the additional Nanjing manufacturing site further strengthens the product’s supply chain capabilities, providing more stable supply assurance for the U.S. market. Jianyou is an integrated pharmaceutical group focusing on R&D, production, and sales, with core business centered on heparin API and formulation supply. It has over 80 ...
- Source: drugdu
- 93
- September 3, 2026
Beyond Glycemic Control! Lilly’s Tirzepatide Receives FDA Approval for Cardiovascular Risk Reduction | Approval Alert

On September 1, Eli Lilly announced that the U.S. Food and Drug Administration (FDA) has officially approved tirzepatide (brand name: Mounjaro) for a new indication to reduce the risk of major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke, in adults with type 2 diabetes at high risk for these events. With this approval, tirzepatide becomes the world’s first GIP/GLP-1 dual receptor agonist approved for this indication. Tirzepatide is an innovative dual-target metabolic drug that simultaneously activates GLP-1 and GIP receptors, offering multiple benefits including potent glycemic control, weight loss, and improvement of metabolic disorders. It was previously approved overseas for type 2 diabetes glycemic control and adult obesity or overweight management, with continuously expanding clinical applications. This cardiovascular protection indication approval is supported by data from the large-scale Phase 3 SURPASS-CVOT study involving over 13,000 participants, fully validating the drug’s cardiovascular benefit in diabetes ...
- Source: drugdu
- 97
- September 3, 2026
First New Therapy in Nearly 30 Years! FDA Approves Besremi for Essential Thrombocythemia | Approval Alert

On September 1, the U.S. Food and Drug Administration (FDA) approved PharmaEssentia’s Besremi (ropeginterferon alfa-2b) for adults with essential thrombocythemia (ET). This marks the first new FDA-approved treatment for ET in nearly 30 years. Essential thrombocythemia is a type of myeloproliferative neoplasm in which the bone marrow produces too many platelets, increasing the risk of potentially serious blood clots, including strokes, heart attacks, and pulmonary embolisms. Some patients may also experience abnormal bleeding or an enlarged spleen. Besremi is a long-acting interferon therapy previously approved for polycythemia vera (PV), another myeloproliferative neoplasm characterized by overproduction of red blood cells. This expanded approval allows use of Besremi in adults with ET regardless of disease status or genetic subtype, including newly diagnosed patients who have not previously received cytoreductive therapy. The approval is based on results from the global Phase 3 SURPASS-ET study, which compared Besremi with anagrelide in ET patients who ...
- Source: drugdu
- 90
- September 3, 2026
Filling Domestic Gap! Hengrui’s First Long-Acting Insulin Ruihengying® Launches Online on Sept 1 | Industry News

On September 1, Hengrui Pharmaceuticals’ self-developed Class 1 innovative biologic, insulin degludec injection (brand name: Ruihengying®), officially launched on the Ali Health platform. This product is the first domestically developed long-acting insulin analog in China, indicated for the treatment of adult type 2 diabetes. From receiving NMPA marketing approval at the end of July to online launch, it took only one month, which industry observers say reflects the accelerating flow of innovative drugs from regulatory approval to patient access in China. Insulin degludec injection (development code: INS068) is a long-acting basal insulin with durable and stable action, with cumulative R&D investment of approximately 544 million yuan. Two pivotal Phase III clinical studies showed that for Chinese type 2 diabetes patients, the drug’s glycemic control is comparable to insulin glargine, with a lower risk of nocturnal hypoglycemia than the comparator, directly addressing a long-standing clinical pain point and better meeting the ...
- Source: drugdu
- 80
- September 3, 2026
Medical Fair Asia

Organiser：Messe Düsseldorf GmbH Time：September 9th – 11th, 2026 Address：10 Bayfront Avenue, Singapore, Singapore Exhibition hall：Sands Expo & Convention Centre Product range: Emergency room equipment Building technology and services Communication and information technology Dental equipment and supplies Diagnosis, disinfection and processing systems Electronic medical instruments, medical technology Catering and kitchen equipment Textiles and laundry services Medical furniture and equipment Laboratory equipment Medical consumables Ophthalmic products Rehabilitation equipment, orthopedic consumables Pharmaceutical products Services and publications About Medical Fair Asia： Medical Fair Asia, founded in 1997, is the largest medical industry exhibition in Singapore and one of the most well-known medical exhibitions in Asia. It showcases a full range of products and services covering the entire field from outpatient treatment to inpatient care, with exhibits including medical devices, medical furniture and equipment, medical site construction technology, and medical facility management. Both exhibitors and visitors at Medical Fair Asia have achieved fruitful ...
- Source: drugdu
- 70
- September 3, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.